Ilika (AIM:IKA) says it's now a revenue-generating business, with initial royalties from its Stereax miniature solid-state batteries expected in its 2027 financial year. Releasing its 2026 results, the company said its larger Goliath battery is also attracting interest from defence and e-bike markets, including a collaboration with Brompton Bicycle. Allergy Therapeutics (AIM:AGY) says revenue growth accelerated in its second half, with full-year revenue up 9% to £59.9 million. Double-digit growth is expected next year as Grassmuno enters its first full peak treatment season. Ecora Royalties (LSE:ECOR) saw its quarterly portfolio contribution jump 61% to $19 million, driven by record cobalt receipts from Voisey's Bay. Net debt has fallen to $74.9 million and the company expects further deleveraging through the rest of 2026. European Green Transition (AIM:EGT) says its wind services business is on track for £17-18 million in revenue this year after a strong first half. The company's repowering pipeline stands at 65 signed heads of terms across a 900-turbine customer base. Rockfire Resources (LSE:ROCK) has returned its best drilling result yet at its Molaoi zinc deposit in Greece, with grades appearing to strengthen at depth. A new drilling rig is due to arrive in Athens in late September. Bradda Head Lithium (AIM:BHL) has secured a drilling contractor for its Arizona lithium campaign, with the rig expected to mobilise by end of July. The programme targets a maiden resource estimate at Whistlejacket by the end of 2027. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million,...

Cordiant Digital Infrastructure (LSE:CORD, FRA:86L) has secured two new customer agreements at its Hudson Interxchange data centre in New York, lifting contracted capacity to around 80% of the floor's saleable space. Billing on the first contract starts in September, with full deployment expected by year-end. Helium One Global Ltd (AIM:HE1, FRA:9K3) says its Colorado joint venture has completed its first helium sale under a short-term offtake agreement after its second commercial helium trailer delivery. With regular exchanges now scheduled, the focus is shifting towards recurring sales and cash flow as production stabilises. Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) is expanding its UAE strategy beyond AI data centres into water, energy and critical infrastructure. Management says growing AI facilities need not just power but also secure water supplies for cooling. Gaming Realms PLC (LSE:GMR, OTCQX:PSDMF, FRA:RNE1) says core content licensing revenue grew 9% in the first half despite a sharp rise in UK gambling tax. The company has now entered 33 regulated markets, including Alberta on its first day of legalised online gaming. Frontier IP Group PLC (LSE:FIPP, FRA:8WT) says portfolio company Pulsiv has appointed Delta Matrix as its first manufacturing partner for products using its energy-efficient OSMIUM power conversion technology. The deal targets a market of around 600 million USB-enabled socket installations per year. Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has appointed former HSBC banker Helge Weiner-Trapness as executive chairman as it explores a dual primary listing in Hong Kong. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has appointed former HSBC banker Helge Weiner-Trapness as executive chairman as the biotechnology group explores a potential dual primary listing in Hong Kong. Weiner-Trapness, who joined the group as chief strategy officer and an...

A successful rollout of its newly launched grass-pollen treatment is ste put Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) on the path to self-sustaining profitability. That's according to Cavendish, the AIM-listed biotech's house broker, which cites management's previous commentary...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the immunotherapy company, expects commercial momentum to build through the second half of its financial year as its newly launched Grassmuno grass pollen treatment gains traction in Germany, while planning advances for a phase IIb trial of...

AIM-listed biotech reports biomarker results suggesting its VLP Peanut treatment could work in as few as three injections Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed allergy immunotherapy company, has reported positive biomarker results from its PROTECT Phase I/IIa...

The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the AIM-listed biotechnology company specialising in allergy treatments, said it would present positive clinical and...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has put fresh debt funding in place after agreeing a new £40m committed senior secured term loan from Hayfin, designed to replace the £20m uncommitted incremental option embedded in its 2024 financing package. The AIM-listed allergy...